Theratechnologies Inc
TSX:TH

Watchlist Manager
Theratechnologies Inc Logo
Theratechnologies Inc
TSX:TH
Watchlist
Price: 2.6 CAD 0.78% Market Closed
Market Cap: 119.5m CAD
Have any thoughts about
Theratechnologies Inc?
Write Note

Theratechnologies Inc
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Theratechnologies Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Theratechnologies Inc
TSX:TH
Total Receivables
$10.7m
CAGR 3-Years
-7%
CAGR 5-Years
-1%
CAGR 10-Years
60%
B
Bright Minds Biosciences Inc
CNSX:DRUG
Total Receivables
CA$110.2k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ESSA Pharma Inc
NASDAQ:EPIX
Total Receivables
$163k
CAGR 3-Years
-31%
CAGR 5-Years
-16%
CAGR 10-Years
5%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Total Receivables
$36.5m
CAGR 3-Years
55%
CAGR 5-Years
136%
CAGR 10-Years
80%
Covalon Technologies Ltd
XTSX:COV
Total Receivables
CA$6.3m
CAGR 3-Years
3%
CAGR 5-Years
-2%
CAGR 10-Years
20%
Spectral Medical Inc
TSX:EDT
Total Receivables
CA$337k
CAGR 3-Years
-16%
CAGR 5-Years
2%
CAGR 10-Years
-6%
No Stocks Found

Theratechnologies Inc
Glance View

Market Cap
119.5m CAD
Industry
Biotechnology

Theratechnologies, Inc. is a pharmaceutical company. The company is headquartered in Montreal, Quebec and currently employs 87 full-time employees. The firm has two approved products: EGRIFTA SV in the United States, and Trogarzo in the United States, the European Union and the United Kingdom. EGRIFTA SV (tesamorelin for injection) is developed for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy. Trogarzo (ibalizumab-uiyk) is developed for HIV treatment. The treatment is infused every two weeks. The company is a new class of antiretrovirals (ARV), and is a long-acting ARV therapy that can lead to an undetectable viral load in combination with other ARVs. The firm markets its prescription products in the United States, Europe and Canada. Its research pipeline is focused on specialized therapies addressing unmet medical needs in HIV, oncology and non-alcoholic steatohepatitis (NASH).

TH Intrinsic Value
6.42 CAD
Undervaluation 60%
Intrinsic Value
Price

See Also

What is Theratechnologies Inc's Total Receivables?
Total Receivables
10.7m USD

Based on the financial report for Aug 31, 2024, Theratechnologies Inc's Total Receivables amounts to 10.7m USD.

What is Theratechnologies Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
60%

Over the last year, the Total Receivables growth was 17%. The average annual Total Receivables growth rates for Theratechnologies Inc have been -7% over the past three years , -1% over the past five years , and 60% over the past ten years .

Back to Top